Zheng Quan Shi Bao Wang·2025-07-30 13:16Core Insights - Shanghai Pharmaceuticals Holding Co., Ltd. ranked 407th in the 2025 Fortune Global 500 list, marking its sixth consecutive year on the list, reflecting its sustainable development and enhanced core competitiveness [2] - In the 2025 Fortune China 500 list, the company ranked 98th, second among pharmaceutical companies, showcasing its strong position in the industry [4] Financial Performance - For the full year of 2024, the company achieved a revenue of RMB 275.25 billion, a year-on-year increase of 5.75%, and a net profit attributable to shareholders of RMB 4.55 billion, up 20.82% year-on-year [4] - In the first half of 2025, the company expects to achieve a net profit attributable to shareholders of approximately RMB 4.45 billion, representing a year-on-year growth of about 52% [4] Industrial and Commercial Operations - The pharmaceutical manufacturing segment operates production bases in 12 provinces in China and overseas, producing around 800 drug specifications and over 30 dosage forms, with multiple products certified by WHO, FDA, and EU [5] - The commercial segment has a distribution network covering all 31 provinces in China, with commercial sales revenue exceeding RMB 250 billion for the first time in 2024, driven by network expansion and management integration [5] Research and Development - The company has 54 new drug candidates in clinical trial stages, including 40 innovative drugs and 14 modified new drugs, with 44 products generating over RMB 100 million in sales, including 2 products exceeding RMB 1 billion [5] International Expansion - Shanghai Pharmaceuticals is actively expanding into international markets, using Hong Kong as a base to register and launch traditional Chinese medicine, while also targeting Southeast Asia and the Middle East to enhance the global influence of Chinese pharmaceutical brands [5] Future Outlook - The company aims to strengthen its role as a "chain leader" enterprise, focusing on solidifying its foundation, enhancing core capabilities, and driving innovation, with a goal of becoming a world-class enterprise and contributing to global health [5]